Floatz logo

bhb810

Gastroesophageal Cancer (GC)

BigHat Biosciences, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

46 Active assets in the Gastroesophageal Cancer (GC) cohort.

Asset / SponsorPhaseRating
Eloxatin
Incyte Corporation
Phase 1/2B
FLUOROURACILUM
Incyte Corporation
Phase 1/2B
Carboplatin
Iambic Therapeutics, Inc
Phase 1/2B
Cyclophosphamide
Diwakar Davar
Phase 2B
Pembrolizumab
Diwakar Davar
Phase 2B

View all 50 →

Same molecule, other indications

bhb810 is also rated in:

gastroesophageal junction adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
digestive system cancerDormant
CCC
Indicative ·
48 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →